Research Progress on Correlations between P53 and Colorectal Cancer
DOI:
https://doi.org/10.53469/jcmp.2025.07(02).11Keywords:
Colorecta cancer, P53, Natural Products, CompoundsAbstract
Colorectal cancer is currently an important health problem worldwide. However, existing treatments fail to meet the need for a radical cure. Additionally, treatment is limited due to toxic side effects and acquired drug resistance. P53 is a tumor suppressor gene encoding P53 protein, which has a significant potential role in the occurrence, development and treatment of colorectal cancer. Many natural products and compounds have been found to interfere with the progression of colorectal cancer by regulating P53, but systematic reviews are lacking. This study systematically reviewed the introduction of P53, the relationship between P53 and the occurrence, development and treatment of colorectal cancer, and the regulation of P53 by natural products and compounds against colorectal cancer. This provides the theoretical foundation for the treatment of colorectal cancer and offer new ideas for the development of novel therapeutic agents for this disease.
References
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
LEVINE A J. p53, the cellular gatekeeper for growth and division [J]. Cell, 1997, 88(3): 323-331.
VOGELSTEIN B, LANE D, LEVINE A J. Surfing the p53 network [J]. Nature, 2000, 408(6810): 307-310.
HOLLSTEIN M, RICE K, GREENBLATT M S, et al. Database of p53 gene somatic mutations in human tumors and cell lines [J]. Nucleic acids research, 1994, 22(17): 3551-3555.
Comprehensive molecular characterization of human colon and rectal cancer [J]. Nature, 2012, 487(7407): 330-337.
NAKAYAMA M, OSHIMA M. Mutant p53 in colon cancer [J]. Journal of molecular cell biology, 2019, 11(4): 267-276.
WANG S, ZHANG Y, HUANG J, et al. TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression [J]. Cancer research, 2019, 79(16): 4086-4098.
MENG F, AI C, YAN G, et al. Tumor-suppressive zinc finger protein 24 (ZNF24) sensitizes colorectal cancer cells to 5-fluorouracil by inhibiting the Wnt pathway and activating the p53 signaling [J]. Experimental cell research, 2023, 433(1): 113796.
YIN Y, JIANG Z, FU J, et al. Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein [J]. Cancer letters, 2022, 525: 55-66.
WANG D, WEI X, CHEN X, et al. GRIM-19 inhibits proliferation and induces apoptosis in a p53-dependent manner in colorectal cancer cells through the SIRT7/PCAF/MDM2 axis [J]. Experimental cell research, 2021, 407(1): 112799.
LIU X, LIU Y, LIU Z, et al. CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner [J]. Molecular cancer, 2021, 20(1): 114.
WANG X W, JIANG Y H, YE W, et al. SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis [J]. Cancer biology & therapy, 2023, 24(1): 2235770.
XIN Z, HU C, ZHANG C, et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis [J]. Redox biology, 2024, 77: 103362.
XU H, WANG T, NIE H, et al. USP36 promotes colorectal cancer progression through inhibition of p53 signaling pathway via stabilizing RBM28 [J]. Oncogene, 2024, 43(47): 3442-3455.
HUANG C, WU S, LI W, et al. Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination [J]. EBioMedicine, 2019, 48: 248-263.
YANG Y, YUAN H, ZHAO L, et al. Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer [J]. Cell death and differentiation, 2022, 29(11): 2177-2189.
FLETCHER J I, WILLIAMS R T, HENDERSON M J, et al. ABC transporters as mediators of drug resistance and contributors to cancer cell biology [J]. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016, 26: 1-9.
YANG C, ZHOU Q, LI M, et al. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines [J]. Scientific reports, 2016, 6: 33078.
LEI G, LIU S, YANG X, et al. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell [J]. Canadian journal of gastroenterology & hepatology, 2021, 2021: 8870907.
DI Y, JING X, HU K, et al. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity [J]. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 2023, 66: 100909.
LAI Q, LI Q, HE C, et al. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis [J]. Aging, 2020, 12(16): 16270-16293.
QIU Z, QIU S, MAO W, et al. LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer [J]. Experimental biology and medicine (Maywood, NJ), 2023, 248(6): 457-468.
ZHOU F, GAO H, SHANG L, et al. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer [J]. Journal of experimental & clinical cancer research: CR, 2023, 42(1): 150.
FELDMAN H C, GHOSH R, AUYEUNG V C, et al. ATP-competitive partial antagonists of the IRE1α RNase segregate outputs of the UPR [J]. Nature chemical biology, 2021, 17(11): 1148-1156.
CHERN Y J, WONG J C T, CHENG G S W, et al. The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer [J]. Cell death & disease, 2019, 10(7): 504.
EBRAHIMI M, BABAEI E, NERI F, et al. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines [J]. International journal of pharmaceutics, 2021, 601: 120592.
NAQISHBANDI A M. Cytotoxic and apoptotic potential of gemini-chrysophanol nanoparticles against human colorectal cancer HCT-116 cell lines [J]. BMC pharmacology & toxicology, 2022, 23(1): 56.
LI J, SHANG L, ZHOU F, et al. Herba Patriniae and its component Isovitexin show anti-colorectal cancer effects by inducing apoptosis and cell-cycle arrest via p53 activation [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, 168: 115690.
CHEE C W, MOHD HASHIM N, NOR RASHID N. Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells [J]. Chemico-biological interactions, 2024, 392: 110928.
HE Z Y, SHI C B, WEN H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin [J]. Cancer investigation, 2011, 29(3): 208-213.
KOTHA R R, LUTHRIA D L. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects [J]. Molecules (Basel, Switzerland), 2019, 24(16).
WANG K, LIU W, XU Q, et al. Tenacissoside G synergistically potentiates inhibitory effects of 5-fluorouracil to human colorectal cancer [J]. Phytomedicine: international journal of phytotherapy and phytopharmacology, 2021, 86: 153553.
PERNICOVA I, KORBONITS M. Metformin--mode of action and clinical implications for diabetes and cancer [J]. Nature reviews Endocrinology, 2014, 10(3): 143-156.
COYLE C, CAFFERTY F H, VALE C, et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis [J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2016, 27(12): 2184-2195.
TRIGGLE C R, MOHAMMED I, BSHESH K, et al. Metformin: Is it a drug for all reasons and diseases? [J]. Metabolism: clinical and experimental, 2022, 133: 155223.
CHEN L, LIAO F, JIANG Z, et al. Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy [J]. British journal of pharmacology, 2020, 177(17): 3991-4006.
ZHANG T, HU L, TANG J F, et al. Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines [J]. Molecules (Basel, Switzerland), 2021, 26(7).
CERVELLI M, PIETROPAOLI S, SIGNORE F, et al. Polyamines metabolism and breast cancer: state of the art and perspectives [J]. Breast cancer research and treatment, 2014, 148(2): 233-248.
JIA Y, MA Z, LIU X, et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect [J]. Cancer medicine, 2015, 4(11): 1730-1741.
BUCKLEY C E, O'BRIEN R M, NUGENT T S, et al. Metformin is a metabolic modulator and radiosensitiser in rectal cancer [J]. Frontiers in oncology, 2023, 13: 1216911.
CHEN L, JIANG J, CHENG C, et al. P53 dependent and independent apoptosis induced by lidamycin in human colorectal cancer cells [J]. Cancer biology & therapy, 2007, 6(6): 965-973.
KELLAND L R, ABEL G, MCKEAGE M J, et al. Preclinical antitumor evaluation of bis – acetate – ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug [J]. Cancer research, 1993, 53(11): 2581-2586.
KALIMUTHO M, MINUTOLO A, GRELLI S, et al. Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells [J]. Acta pharmacologica Sinica, 2011, 32(11): 1387-1396.
KANG M A, KIM M S, KIM J Y, et al. A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells [J]. International journal of oncology, 2015, 46(1): 342-350.
YANG L, LIANG Q, SHEN K, et al. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, 71: 70-78.
ATTANZIO A, D'AGOSTINO S, BUSà R, et al. Cytotoxic Activity of Organotin (IV) Derivatives with Triazolopyrimidine Containing Exocyclic Oxygen Atoms [J]. Molecules (Basel, Switzerland), 2020, 25(4).
IQBAL S, FIRDOUS F, FURQAN M, et al. Synthesis and characterization of bis-amide SSE1917 as a microtubule-stabilizing anticancer agent [J]. Bioorganic chemistry, 2024, 143: 107094.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Shenkang Tang, Haijuan Xiao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
